Animal studies have shown potential risks to the developing baby, and human pregnancy data are very limited
It remains too early to assess the long-term impact on the market given questions on reimbursement and safety profile. Do people need fewer knee or hip replacements as the wear and tear on their joints is reduced
Bottom line: Microdosing sounds like a nice idea for a class of drugs with common side effects during the initiation/dose escalation phase of treatment
A study reported that there was no difference in post-prandial plasma incretin concentrations between diffuse and focal cases, and no difference in baseline plasma incretin concentration between focal, diffuse, and transient hyperinsulinism ( Studies in a mouse model of K ATP hyperinsulinism, the most common and severe genetic subtype of hyperinsulinism, have shown that the GLP-1 receptor antagonist exendin-(9-39) significantly increases fasting plasma glucose and decreases the insulin to glucose ratio on the fasting state, effectively reversing the hyperinsulinemic hypoglycemia phenotype
Benefits of MOTS-c Peptide Based on current scientific literature, the areas where MOTS-c shows the most promising effects include: - Improved insulin sensitivity and glucose metabolism: Multiple animal studies have demonstrated improvements in glucose tolerance and insulin sensitivity with MOTS-c treatment - Metabolic health and weight management: By activating AMPK and enhancing fat oxidation, MOTS-c may help achieve/maintain healthier body composition, particularly in the context of diet-induced or age-related metabolic decline - Exercise capacity and endurance: MOTS-c has been shown to improve exercise capacity in animal studies, possibly due to mitochondrial efficiency as well as enhanced muscle metabolism - Healthy aging: MOTS-c is one of the well-studied peptides when it comes to longevity
